Literature DB >> 11558784

P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy.

W X Yan1, J J Archelos, H P Hartung, J D Pollard.   

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is widely regarded as an autoimmune disorder, although the autoantigen remains unknown. In this study, the sera of 21 CIDP patients were examined by immunofluorescence for antimyelin activity and by Western blotting for binding to myelin proteins. Six sera contained anti-P0 immunoglobulin G antibodies, and four of these caused conduction block and demyelination following intraneural injection in experimental animals. Absorption with P0 protein eliminated the demyelinating activity. These results show that P0 is an autoantigen in some patients with CIDP. Since P0 possesses powerful adhesion properties and is largely responsible for myelin compaction, the demonstration of demyelination by human anti-P0 antibodies provides new insight into this important and common immunopathological process.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11558784     DOI: 10.1002/ana.1129

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  32 in total

Review 1.  Peripheral neuropathy.

Authors:  Richard A C Hughes
Journal:  BMJ       Date:  2002-02-23

Review 2.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 4.  Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Man Mohan Mehndiratta; Avinash Chandra Singh
Journal:  Curr Allergy Asthma Rep       Date:  2007-07       Impact factor: 4.806

5.  Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy.

Authors:  Hye-Jung Kim; Cha-Gyun Jung; Mark A Jensen; Danuta Dukala; Betty Soliven
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

6.  CD19 as a therapeutic target in a spontaneous autoimmune polyneuropathy.

Authors:  P M Abraham; S H Quan; D Dukala; B Soliven
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 7.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 8.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

9.  Serum IgG antibodies to P0 dimer and 35 kDa P0 related protein in neuropathy associated with monoclonal gammopathy.

Authors:  A Favereaux; A Lagueny; A Vital; J-M Schmitter; S Chaignepain; X Ferrer; I Labatut-Cazabat; C Vital; K G Petry
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

10.  Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.

Authors:  Mohamed Mahdi-Rogers; Yusuf A Rajabally
Journal:  Biologics       Date:  2010-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.